SWOG

Name

SWOG

Legal name

SWOG Cancer Research Network

Website

https://swog.org

Company type

Private

Founded year

1956

Operating status

Operating

Headcount range

51–100 employees

Ownership category

akta.pro rank

Product category

Cancer Clinical Trials Research

NAICS

Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Health Services (8000)

akta.pro primary industry

Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL)

akta.pro secondary industries

Clinical CROs (Phase I–IV) (HLAGAAAA), Clinical Trial Site Operations & Study Coordination (HLAGACAE), Investigator & Site Training / GCP Support (HLAGACAF)

Keywords

• Cancer clinical trials
• Cooperative oncology research
• Clinical trial design
• Publicly funded trials
• NCI network research

Headquarters

HQ city

Portland

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D

Revenue model

1. Federal NCI Funding: Publicly funded by the National Cancer Institute (NCI) as part of the National Clinical Trials Network (NCTN). This is the primary funding source supporting the organization's operations and clinical trial activities.
2. Philanthropic Support: The Hope Foundation for Cancer Research, SWOG's public charity, raises millions of dollars from individuals and organizations who support cancer research. By 2016, The Hope Foundation had provided more than $30 million in research support to SWOG.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Core offering

SWOG is a non-profit cancer research cooperative group that designs and conducts publicly funded clinical trials as part of the National Cancer Institute's National Clinical Trials Network. The organization operates multiple precision medicine and pragmatic oncology trials, manages a centralized biospecimen bank, and supports training programs and fellowships for clinical investigators.

Product overview

SWOG Cancer Research Network is a global cancer research community that designs and conducts publicly funded clinical trials as part of the NCI's National Clinical Trials Network (NCTN). The organization operates a diverse portfolio of clinical trial programs including Lung-MAP (precision medicine umbrella trial for lung cancer), DART (immunotherapy trial for rare cancers), and myeloMATCH (precision oncology umbrella trial for myeloid malignancies). SWOG functions as both an NCTN research group and an NCORP research base, conducting treatment trials, prevention studies, cancer control research, and survivorship studies through its committee structure. The network provides research infrastructure including a biospecimen bank with over 1.4 million samples, the ExpertusONE learning management system for training, and patient education materials in English and Spanish. Training programs include the ESITC (Early-Stage Investigator Training Course), LEAP-D course, and Dr. Charles A. Coltman, Jr. Fellowship Program. The Hope Foundation for Cancer Research serves as SWOG's supporting public charity.

Differentiator

Problem solved

Functional benefit

Products and services

• Lung-MAP A precision medicine lung cancer clinical trial designed to evaluate biomarker-driven therapies for patients with advanced non-small cell lung cancer.
• DART A clinical trial focused on rare cancers, evaluating immunotherapy combinations in rare tumor types.
• myeloMATCH A clinical trial program focused on patients with myeloid malignancies, employing molecular profiling to assign treatments.
• S2302 Pragmatica-Lung A pragmatic lung cancer clinical trial designed to streamline study procedures and broaden patient eligibility.
• Biospecimen Bank A centralized repository of patient-derived biological samples supporting correlative science within SWOG-led trials.
• Training Programs and Fellowships Educational programs and fellowships supporting the development of clinical investigators within the SWOG network.

Quantifiable outcome

• 15 FDA approvals of new cancer therapies
• +6 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration6 records

Feature3 records

Partnerships

Ten partnerships are on record, tiered core, major and regional.

• National Cancer Institute (NCI)coreStrategic or Co-development Partner · 1 January 1956SWOG is a member of the NCI's National Clinical Trials Network (NCTN), receiving federal funding to conduct publicly funded clinical trials. This is the primary partnership enabling SWOG's research activities.
• The Hope Foundation for Cancer ResearchcoreStrategic or Co-development PartnerSWOG's public charity that raises funds to support the organization's research. By 2016, provided more than $30 million in research support - the most philanthropic support of any NCTN group. Provides programs including travel support, fellowships, and grant-writing workshops.
• Fred Hutchinson Cancer Research CentercoreTechnology or IntegrationHome to SWOG's Statistics and Data Management Center since 1984, providing statistical expertise and data management infrastructure for all SWOG clinical trials.
• Oregon Health & Science University (OHSU) Knight Cancer InstitutecoreStrategic or Co-development PartnerCurrent headquarters location for SWOG. Group Chair Charles D. Blanke, MD leads from this institution since 2013. Hosts group operations and leadership.
• Cold Spring Harbor LaboratorymajorStrategic or Co-development PartnerFirst NCI basic science center to partner with a cooperative group when Cold Spring Harbor Laboratory became a SWOG member in 2011.
• The Jackson LaboratorymajorStrategic or Co-development PartnerBecame a SWOG member in 2013, significantly expanding the group's translational medicine expertise.
• MD Anderson Cancer CentermajorStrategic or Co-development PartnerOriginal founding location of SWOG in 1956 under Dr. H. Grant Taylor at MD Anderson Hospital in Houston. Continues as a major member institution.
• University of MichiganmajorStrategic or Co-development PartnerPrevious headquarters location under Group Chair Laurence Baker, DO (2005-2013). Continues as an active member site.
• NCTN Member GroupsmajorStrategic or Co-development PartnerCollaborative trials with other NCTN groups including Alliance, NRG, and ECOG-ACRIN. For example, PROSPECT-Lung trial co-led by Alliance and SWOG.
• Instituto Nacional de Cancerología (INCan) MexicoregionalStrategic or Co-development PartnerFirst Latin American cancer institute to join SWOG in 2010 as part of the Latin America Initiative. INCan represents SWOG's expansion into international membership.

Scale indicators14 records

Recent moves9 records

Expansion highlights5 records

Direct peers

• NRG Oncology: NCI NCTN cooperative group conducting oncology clinical trials across multiple disease sites. Operates with similar cooperative group governance and NCI funding structure as SWOG.
• Children's Oncology Group (COG): NCI-supported cooperative group focused on pediatric cancer trials, sharing the cooperative group model and NCI NCTN affiliation with SWOG, though focused on pediatric populations.
• Alliance for Clinical Trials in Oncology: Another NCI NCTN cooperative group focused on oncology clinical trials. Alliance and SWOG co-led the PROSPECT-Lung trial, demonstrating direct operational overlap in oncology trial design and execution.
• ECOG-ACRIN Cancer Research Group: NCI NCTN cooperative group conducting cancer clinical trials with similar member institution model, NCI funding, and trial portfolio as SWOG.

Broad incumbents

• IQVIA: Largest global commercial CRO with extensive oncology capabilities. Competes with SWOG for pharma-sponsored oncology trial work and offers global reach and faster startup timelines.
• ICON plc: Major global CRO with significant oncology and clinical trial management capabilities, competing with cooperative groups for commercial oncology trial contracts.
• National Cancer Institute (NCI): The federal parent entity that funds and oversees SWOG through the NCTN. NCI sets research priorities, provides funding, and distributes protocols via the CTSU system.
• PPD (Thermo Fisher Scientific): Large commercial CRO acquired by Thermo Fisher, offering comprehensive clinical trial services including oncology. Competes for pharma-sponsored trials that might otherwise go to cooperative groups.
• Labcorp Drug Development (Fortrea): Major commercial CRO offering central laboratory and clinical trial services. Competes with SWOG's clinical trial operations and central laboratory functions.

Others

• Fred Hutchinson Cancer Center: Hosts SWOG's Statistics and Data Management Center since 1984. Acts as a key infrastructure partner providing statistical and data management capabilities to SWOG.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xtwitter.com/SWOG
• YouTubeyoutube.com/user/SWOGCancerResearch
• LinkedInlinkedin.com/company/swog---leading-cancer-research

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SWOG